AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02594358
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING
Trial: NCT01163435
Drug: sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days
Trial: NCT00843024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match
Trial: NCT01466647
Drug: AXL1717
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
Trial: NCT00640991
Drug: glulisine insulin, glargine insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of glulisine, SC injection of glargine
Trial: NCT03447353
Drug: Norco 10Mg-325Mg Tablet
RxNorm normalized name: Norco 10mg-325mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose on two of the four study visits, one in conjunction with 1mg alprazolam
Trial: NCT03447353
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose on two of the four study visits, double dose on one of the four study visits
Trial: NCT03355716
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl (30.0 Mc)
Trial: NCT04037891
Drug: rVA576
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.
Trial: NCT04037891
Drug: rVA576
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
Trial: NCT04167670
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets administered orally.
Trial: NCT05217472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Injection
Trial: NCT05217472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection
Trial: NCT00462345
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
Trial: NCT01373593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03344393
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous normal saline infusion intraoperatively
Trial: NCT02927626
Drug: Yang Yin Fu Zheng therapy
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yang Yin Fu Zheng is a Chinese herbal compound.
Trial: NCT02927626
Drug: Routine medical care
RxNorm normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medical care
Trial: NCT02903108
Drug: SRP plus placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP followed by placebo gel placement into intrabony defect
Trial: NCT00372983
Drug: NOV-205
RxNorm normalized name: Dallergy Reformulated Nov 2011
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01594762
Drug: Topical placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 days of treatment
Trial: NCT00000329
Drug: Opioid-Related Disorders
RxNorm normalized name: DRUGS FOR ACID RELATED DISORDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01730469
Drug: AT1001 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT1001 150mg is available as a capsule
Trial: NCT00533598
Drug: MK0557
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01265550
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
Trial: NCT03638466
Drug: SPN-810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of SPN-810 36 mg on neuronal brain activity, GABA and Glutamate levels and on the aggression score
Trial: NCT03638466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of placebo on neuronal brain activity, GABA and Glutamate levels and on the aggression score
Trial: NCT03409835
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 2 ml is administered after induction of general anesthesia.
Trial: NCT00115102
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02267187
Drug: General Anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
Trial: NCT00408694
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01692301
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tablet
Trial: NCT01692301
Drug: LCZ696 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 Matching Placebo tablet
Trial: NCT01487200
Drug: FX006 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single 3 mL IA injection
Trial: NCT01487200
Drug: FX006 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single 3 mL IA injection
Trial: NCT01487200
Drug: FX006 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single 3 mL IA injection
Trial: NCT01487200
Drug: TCA IR 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single 1 mL IA injection
Trial: NCT03133260
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg acetylsalicylic acid will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
Trial: NCT03133260
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg atorvastatin will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
Trial: NCT02837783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, one daily
Trial: NCT00920712
Drug: Weiqi decotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decoction ,two times a day
Trial: NCT02097147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, once per day.
Trial: NCT04071184
Drug: Alofanib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five dose cohorts and expanded cohort will be included
Trial: NCT00037609
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 taken by mouth twice daily.
Trial: NCT00520130
Drug: Conditioning Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3.~Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3
Trial: NCT00017862
Drug: SCH55700
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00480610
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application
Trial: NCT04223960
Drug: EA1080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA1080 Formulation A.
Trial: NCT04223960
Drug: EA1080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA1080 Formulation B.
Trial: NCT04223960
Drug: EA1080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA1080 Formulation C.
Trial: NCT04223960
Drug: EA1080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA1080 Formulation D.
Trial: NCT04223960
Drug: EA1080-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA1080-matching placebo.
Trial: NCT04223960
Drug: EA1080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA1080 Formulation E.
Trial: NCT04223960
Drug: EA1080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA1080 Formulation F.
Trial: NCT00126087
Drug: dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004183
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00631137
Drug: testosterone gel applied to skin
RxNorm normalized name: testosterone Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of testosterone gel
Trial: NCT04455711
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous infusion of remifentanil 1.5 ng/ml until extubation
Trial: NCT01014403
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle
Trial: NCT01096563
Drug: AZD9164
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder for inhalation via Turbuhaler, JSMAD. A single dose of AZD9164 on Day 1 and repeated dosing on Day 4 to day 15 (JSMAD).~The starting dose will be 400 μg delivered dose and subsequent doses are planned to be 1000 μg and 2800 μg delivered dose.
Trial: NCT01096563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder for inhalation via Turbuhaler, JSMAD.
Trial: NCT02711137
Drug: INCB057643
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial cohort dose of INCB057643 at the protocol-specified starting dose (Part 1), with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts (Part 2).
Trial: NCT00389389
Drug: AZD4877
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT00105443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib-matching placebo tablets were orally administered twice daily (bid).
Trial: NCT02562742
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF 400 mg tablets administered orally once daily
Trial: NCT00622895
Drug: Mycophenolic Acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00769119
Drug: AZD9668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 30 mg, oral tablet, twice daily for 28 days
Trial: NCT00769119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x Matched placebo, oral tablet, twice daily for 28 days
Trial: NCT03887130
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m² twice a day (2000 mg/m² daily) from day 1 to day 14
Trial: NCT00650871
Drug: GW679769
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00650871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00443391
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label study, subjects will take up to 80mg daily for 24 months.
Trial: NCT00947076
Drug: Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00947076
Drug: Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00459420
Drug: Caffeine 100-200 mg BID
RxNorm normalized name: caffeine 200 MG
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo
Trial: NCT00459420
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00849576
Drug: Regular Human Insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.
Trial: NCT00849576
Drug: Insulin VIAject™ (75%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
Trial: NCT00110773
Drug: S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-Caine Peel, composed of a 1:1 (w:w) eutectic mixture of 7% lidocaine and 7% tetracaine, applied topically. S-Caine Peel applied at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
Trial: NCT00110773
Drug: Placebo Peel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
Trial: NCT03016650
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
Trial: NCT03016650
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
Trial: NCT04512235
Drug: cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to institutional standard of care.
Trial: NCT03591458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a supply of Placebo capsules, matching those of Amitriptyline, for the titration, intervention, and taper periods
Trial: NCT02625558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given three times a day
Trial: NCT00706134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken once daily in the morning with a light meal.
Trial: NCT01614132
Drug: maintenance chemotherapy (vincristin, cisplatin and CCNU)
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maintenance chemotherapy of maximum of 8 cycles á 42 days
Trial: NCT00545311
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00545311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03003104
Drug: DMT210 Topical Gel 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03316690
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily treatment with placebo tablets for 101 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-101: Placebo tablet 1000 mg x 2
Trial: NCT03354754
Drug: LYS228
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYS228 IV infusion every 6 hours
Trial: NCT01535781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical syringe and drip used as in the intervention, to ensure blinding.
Trial: NCT00691483
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet taken orally twice daily for 12 weeks
Trial: NCT01494363
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil 2400 mg/m2 (diluted in 1000 ml of 5% dextrose solution) administered as a continuous intravenous infusion over 48 hours every 2 weeks
Trial: NCT03231176
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles
Trial: NCT01494363
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 400 mg/m2 (diluted in 250 ml of 5% dextrose solution) as a 2-hour intravenous infusion every 2 weeks
Trial: NCT03163420
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium 50 mg granules for oral solution
Trial: NCT00578643
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -5 through -2~50 mg/kg
Trial: NCT01436539
Drug: Adefovir Dipivoxil and polyene phosphatidylcholine
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
Trial: NCT00758862
Drug: 2% TD1414 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application 3 times daily for 7 days
Trial: NCT02497001
Drug: Symbicort® Turbuhaler® (TBH) Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03566329
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion with the same rate of infusion as the study drugs
Trial: NCT01737697
Drug: Placebo (acute phase)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.
Trial: NCT01737697
Drug: Placebo ( subacute phase)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
Trial: NCT04340843
Drug: Decitabine and Cedazuridine
RxNorm normalized name: cedazuridine / decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00687518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of equivalent volume of saline serum
Trial: NCT01514682
Drug: Anti-inflammatory Combination Therapy
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening~2. fluvastatin: target dose 40 mg/day, administered in a single evening dose~3. combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose
Trial: NCT01514682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-medication pills; To be taken in morning and evening intervals.
Trial: NCT04421274
Drug: Best medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refer to the latest medication guidelines and give the best medication to the patients
Trial: NCT00046774
Drug: MRA 003 US
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02755857
Drug: Lozanoc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 65 mg
Trial: NCT01262365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
Trial: NCT02439125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: b.i.d. orally for 3 weeks
Trial: NCT02507128
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo were taken 30 min before PCI.
Trial: NCT00639249
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00829309
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg Tablet
Trial: NCT00829309
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg Tablets
Trial: NCT00781456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet daily to match experimental arm
Trial: NCT04369365
Drug: Azithromycin 500 milligram (mg) oral Tablet
RxNorm normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: weekly oral use
Trial: NCT04369365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly oral use
Trial: NCT01148446
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/mq IV, day 1
Trial: NCT01148446
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/mq IV, day 1
Trial: NCT01148446
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/mq IV, day1